Systemic cytokines drive conserved severity-associated myeloid responses across bacterial and viral infections.

Publication date: Jul 23, 2025

Both bacterial and viral infections can trigger an overwhelming host response, leading to immunopathology and organ dysfunction. Multiple studies have reported dysregulated myeloid cell states in patients with bacterial sepsis or severe SARS-CoV-2 infection. However, their relevance to viral infections other than COVID-19, the factors driving their induction, and their role in tissue injury remain poorly understood. Here, we performed a multi-cohort analysis of single cell and bulk transcriptomic data from 1845 patients across 25 studies. Our meta-analysis revealed a conserved severity-associated gene signature pointing to emergency myelopoiesis (EM) and increased IL1R2 expression in monocytes and neutrophils from patients with bacterial sepsis, COVID-19, and influenza. Analysis of tocilizumab-treated COVID-19 patients showed that IL-6 signaling blockade partially reduces this signature and results in a compensatory increase in G-CSF. To validate the role of these cytokines in vivo, we used a mouse model of influenza infection that recapitulates severity-associated increases in IL1R2+ monocytes and IL1R2 neutrophils, and demonstrate that combined IL-6 and G-CSF blockade inhibits their production. Our study demonstrates the cooperative role of G-CSF and IL-6 in driving the production of severity-associated IL1R2+ myeloid cells and highlights the link between myeloid dysregulation and tissue injury during severe infection.

Open Access PDF

Concepts Keywords
Bacterial Animals
Immunopathology Antibodies, Monoclonal, Humanized
Influenza Antibodies, Monoclonal, Humanized
Myeloid Bacterial Infections
Vivo COVID-19
Cytokines
Cytokines
Disease Models, Animal
Granulocyte Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor
Humans
Influenza, Human
Interleukin-6
Interleukin-6
Mice
Monocytes
Myeloid Cells
Myelopoiesis
Neutrophils
Orthomyxoviridae Infections
SARS-CoV-2
Sepsis
tocilizumab

Semantics

Type Source Name
disease MESH viral infections
disease IDO host
disease IDO cell
disease MESH sepsis
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO role
disease MESH emergency
disease MESH influenza
drug DRUGBANK Tocilizumab
drug DRUGBANK Filgrastim
pathway REACTOME Influenza Infection
disease IDO production
disease MESH infection
disease IDO primary infection
disease IDO pathogen
disease MESH infectious diseases
drug DRUGBANK Coenzyme M
disease IDO blood
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH respiratory infections
drug DRUGBANK Esomeprazole
pathway KEGG Influenza A
drug DRUGBANK Oxygen
disease MESH respiratory syncytial virus infection
disease MESH inflammation
disease MESH Bacterial Infections
disease MESH Disease Models Animal
disease MESH Orthomyxoviridae Infections

Original Article

(Visited 2 times, 1 visits today)